Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8447421 | European Journal of Cancer | 2011 | 6 Pages |
Abstract
Although this study was retrospective, a 1M-RDI cut-off value of ⩾50% for sorafenib may be the first factor to predict PFS but not OS in cytokine pretreated mRCC patients. The data indicate that a dose of 400 mg/day of sorafenib administered successively for the first one month was necessary to prolong disease stabilisation and could be tolerated by Japanese patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Atsunari Kawashima, Hitoshi Takayama, Yasuyuki Arai, Go Tanigawa, Mikio Nin, Jiro Kajikawa, Tetsuo Imazu, Tatsuya Kinoshita, Yutaka Yasunaga, Hitoshi Inoue, Kenji Nishimura, Shingo Takada, Kazuo Nishimura, Akira Tsujimura, Norio Nonomura,